Biocon Announces Japan Approval for Pegfilgrastim Biosimilar; Sandoz to Exclusively Market Product
Biocon Limited has announced a significant regulatory milestone in Japan after its wholly owned subsidiary, Biocon Biologics Ltd., received marketing approval for its pegfilgrastim biosimilar from Japan’s Ministry of Health, Labour and Welfare (MHLW). The approval, announced on August 25, 2026, covers a biosimilar version of Neulasta®, a pegfilgrastim product used in supportive cancer care. The product has been developed and manufactured by Biocon Biologics, while Global Regulatory Partners Japan will serve as the Marketing Authorization Holder on behalf of Biocon. Under the arrangement, Sandoz K.K. will have exclusive responsibility for promoting, selling and distributing the product in Japan.
Japan Approval Strengthens Biocon’s Biosimilar Portfolio
The MHLW approval expands Biocon’s biosimilar portfolio in Japan and represents another step in the company’s strategy of increasing access to affordable biologic medicines in international markets. Pegfilgrastim is a long-acting form of granulocyte colony-stimulating factor (G-CSF), used to reduce the risk of chemotherapy-induced neutropenia. By securing regulatory approval in Japan, Biocon Biologics can further expand its presence in the country’s biosimilars market, while the partnership with Sandoz provides an established commercial channel for the product.
Sandoz to Handle Exclusive Commercialisation in Japan
Under the agreement announced by Biocon, Sandoz K.K. will exclusively promote, sell and distribute the pegfilgrastim biosimilar in Japan. This commercial partnership allows Biocon to leverage Sandoz’s presence and capabilities in the Japanese pharmaceutical market while retaining responsibility for the development and manufacturing of the product through Biocon Biologics. Global Regulatory Partners Japan will act as the Marketing Authorization Holder.
Biocon’s Focus on Affordable Medicines
Biocon said the latest approval further strengthens its biosimilar portfolio in Japan and reflects its continued focus on expanding patient access to high-quality and affordable medicines globally. Biosimilars can play an important role in improving access to biologic treatments by providing additional treatment options following the expiry or loss of exclusivity of reference biologic products.
The Japanese approval is strategically important for Biocon because Japan is a highly regulated pharmaceutical market with established demand for high-quality biologic and biosimilar medicines. The approval also provides Biocon Biologics with another opportunity to expand its international commercial footprint through a partnership-led model. The financial contribution from the product will depend on the timing of commercial launch, market adoption, pricing, volumes and other commercial factors; the company statement did not provide specific revenue or profit guidance related to this approval.
Point to consider
Biocon’s pegfilgrastim biosimilar approval in Japan is a positive development for the company’s biosimilars business and international expansion strategy. The product will be manufactured by Biocon Biologics and exclusively commercialised in Japan by Sandoz K.K., while Global Regulatory Partners Japan will serve as the Marketing Authorization Holder. Investors should watch for the commercial launch timeline, product uptake and the potential contribution from the Japanese market in future financial results.
Disclaimer
This article is based on the company statement issued by Biocon Limited on August 25, 2026. The information is provided for informational and educational purposes only and should not be considered investment advice or a recommendation to buy or sell Biocon shares. Future commercial performance may differ depending on regulatory, market, pricing, competition and other business factors. Investors should conduct their own research and consult a SEBI-registered investment adviser before making investment decisions.